Nanobodies Market Size to Exceed USD 2,576.2 Mn by 2032

The Nanobodies Market, estimated at USD 568.3 Mn in 2025, is expected to exhibit a CAGR of 24.1% and reach USD 2,576.2 Mn by 2032.

The market growth is fueled by rising demand for advanced biotechnology solutions that improve healthcare outcomes, along with increasing adoption in areas such as drug development, diagnostics, and personalized medicine. Innovations in genomics, cell and gene therapies, and biomanufacturing, supported by strong R&D investments, are enhancing treatment effectiveness, efficiency, and accessibility. Furthermore, favorable regulatory support, strategic collaborations, and the growing focus on precision medicine are accelerating market expansion and opening new opportunities for industry participants.

Key market players are focusing on adopting growth strategies such as acquisitions, which will drive the global nanobodies market. For instance, in January 2025, Sanofi, a multinational pharmaceutical and healthcare company, announced the acquisition of Kymab, a pharmaceutical company, to add KY1005 to its pipeline. KY1005 is a human monoclonal antibody targeting the key immune system regulator OX40L.

Global Nanobodies Market: Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025, as "coronavirus disease 2025" or COVID-19. The virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation of things from one place to another.
COVID-19 had a positive impact on the global nanobodies market owing to the inorganic activities of research institutes in developing treatments. For instance, in July 2025, DiosCURE Therapeutics SE, a manufacturer of immunotherapeutics, signed an exclusive licensing agreement with research and invention parties such as University Hospital Bonn, Macrostruct Holding & Consulting AB, and Scripps Research for a broad suite of intellectual property, including DIOS203, DIOS202, and DIOS301, highly effective therapies against SARS-CoV-2. The therapy is an option for urgent treatment for COVID-19 patients. These nanobody candidates are expected to be well-tolerated highly efficacious, and cost-efficient in nanobody production, with a wide range of clinical applications.

Global Nanobodies Market: Key Developments

In October 2025, Merck KGaA, a global science and technology company, entered into an out-licensing agreement with Novartis AG, a global healthcare company, for the development of M6495, an anti-ADAMTS5 nanobody, for the potential treatment of osteoarthritis (OA). The increased treatment option for osteoarthritis patients.
In December 2025, Taisho Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, announced the launch of Nanozora (Ozoralizumab) 30 mg syringes for subcutaneous injection, a trivalent anti-TNF nanobody for the treatment of rheumatoid arthritis (RA).
In February 2025, Sanofi received approval from the U.S. Food and Drug Administration for Cablivi (caplacizumab-yhdp) to treat adults with acquired thrombotic thrombocytopenic purpura (aTTP). The Cablivi provides an effective treatment option for people suffering from this disease.
In October 2025, miRecule, Inc., an innovator of next-generation RNA therapeutics, announced a strategic collaboration and exclusive license agreement with Sanofi to develop and commercialize a best-in-class antibody-RNA conjugate (ARC) for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The collaboration marks miRecule’s first licensing transaction leveraging its proprietary DREAmiR platform.

Browse 44 Market Data Tables and 41 Figures spread through 180 Pages and in-depth TOC on “Global Nanobodies Market”- Forecast to 2032, Global Nanobodies Market, By Product (Monovalent Nanobodies, Bivalent Nanobodies, Bispecific Nanobodies, Biparatopic Nanobodies, Multivalent Nanobodies and Fusion Nanobodies), By Therapeutic Area (Oncology, Infectious Diseases, Inflammatory and Autoimmune Diseases, Neurological Disorders, Others), By Application (Therapeutic, Diagnostic, Research), By End User (Hospitals, Biopharmaceutical Companies, Diagnostic Laboratories and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/nanobodies-market-1680

Key Takeaways of the Global Nanobodies Market:

The global nanobodies market is expected to exhibit a CAGR of 24.1% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global nanobodies market.
Among product type, monovalent nanobodies segment is expected to hold a dominant position in the global nanobodies market during the forecast period, and this is attributed to the increasing research and development activities due to the growing use of monovalent nanobodies in different clinical, diagnostic, therapeutic, and research applications. For instance, in September 2025, Avillion LLP, a drug development company, announced the successful completion and positive top-line results of its Phase 2 trial of sonelokinab (M1095) in patients with moderate to severe chronic plaque-type psoriasis. The study evaluated four dose regimens of sonelokinab, placebo and a reference arm of secukinumab.
Among region, North America is expected to be the dominant region in the global nanobodies market, owing to the key players focus on organic strategies such as product launches. For instance, in March 2025, Biotium, Inc., a biotechnology company, announced the launch of Mix-n-Stain labeling kits with new Mix-n-Stain nanobodies labeling kits. These new kits offer rapid and efficient labeling of nanobodies with exceptionally bright and photostable CF dyes.
Major players operating in the global nanobodies market are Merck KGaA, Sanofi, AlpalifeB Inc, GenScript, Novartis International AG, Taisho Pharmaceutical Holdings Co., Ltd., Sino Biological, Inc., GeneMedi, Biocytogen, Abnova Corporation, NanoTag Biotechnologies, Avillion LLP, Capra Science, Numab Therapeutics, CUSABIO TECHNOLOGY LLC, Proteintech Group, Inc., GT Biopharma, Inc., Confo Therapeutics, R&D Systems, Inc., Abcepta Biotech Ltd. Co.